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Background: Tau aggregation inhibitors could treat Alzheimer disease.
Results: Stable reduced forms of leucomethylthioninium (LMTX) are active in blocking prion-like Tau aggregation in novel
cellular models.
Conclusion: The intracellular Ki (0.12 M) is comparable with brain levels required for clinical benefit.
Significance: LMTX could treat Alzheimer disease.
Alzheimer disease (AD) is a degenerative tauopathy charac-
terized by aggregation of Tau protein through the repeat
domain to form intraneuronal paired helical filaments (PHFs).
We report two cell models in which we control the inherent
toxicity of the core Tau fragment. These models demonstrate
the properties of prion-like recruitment of full-length Tau into
an aggregation pathway in which template-directed, endoge-
nous truncation propagates aggregation through the core Tau
binding domain. We use these in combination with dissolution
of native PHFs to quantify the activity of Tau aggregation inhib-
itors (TAIs). We report the synthesis of novel stable crystalline
leucomethylthioninium salts (LMTX), which overcome the
pharmacokinetic limitations of methylthioninium chloride.
LMTX, as either a dihydromesylate or a dihydrobromide salt,
retains TAI activity in vitro and disrupts PHFs isolated fromAD
brain tissues at 0.16M. TheKi value for intracellular TAI activ-
ity, which we have been able to determine for the first time, is
0.12 M. These values are close to the steady state trough brain
concentration of methylthioninium ion (0.18 M) that is
required to arrest progression ofADon clinical and imaging end
points and the minimum brain concentration (0.13 M)
required to reverse behavioral deficits and pathology in Tau
transgenic mice.
Alzheimer disease (AD)3 is an irreversible, neurodegenera-
tive disorder characterized by the formation of neurofibrillary
tangles. These tangleswere discovered byAlzheimer (1) and are
made up of pathological paired helical filaments (PHFs) com-
posed predominantly of a truncated 100-amino acid fragment
of themicrotubule-associated protein Tau (2). Numerous stud-
ies have confirmed correlations between the quantity of aggre-
gated Tau, spread of neurofibrillary tangle pathology, extent of
clinical dementia, and functional molecular imaging deficits
(3–8). There is increasing interest in the possibility of develop-
ing a Tau-based approach to treatment of AD.
We previously reported an assay for Tau-Tau binding
through the repeat domain in which we demonstrated that the
repeat domain has the ability to define a template-directed
truncation of full-length Tau to reproduce a proteolytically sta-
ble species characteristic of the PHF core in AD and that the
process could be propagated through stepwise binding and
digestion cycles (9). We now report the development of two
cell-based assays that permit demonstration of prion-like pro-
cessing of Tau in the more physiological context of the cell.
Compounds which have Tau aggregation inhibitor (TAI) activ-
ity in cell-free assays block template-directed truncationwithin
cells with approximately the same rank order, showing that the
process is aggregation-dependent. These models confirm that
Tau protein, in the absence of any post-translational modifica-
tion or covalent cross-linking, is inherently able to formproteo-
lytically resistant aggregates through the repeat domain in a
physiological environment and that this process recruits nor-
mal Tau to undergo template-directed proteolytic truncation
to form characteristic neofragments, including the core Tau
unit of the PHF.
* This work was supported by grants from TauRx Therapeutics Ltd. C. R. H.
(Chief Scientific Officer), J. M. D. S. (Head of Technical), and C. M. W. (Exec-
utive Chairman) are officers in TauRx Therapeutics Ltd., and C. R. H.,
J. M. D. S., S. C., D. H., A. I., S. J. K., C. P. L., C. M., S. L. N., J. E. R., M. S., J. P. S.,
L. J. S., and C. M. W. are co-inventors on various patents related to this
investigation.
Author’s Choice—Final version full access.
□S This article contains supplemental Tables S1 and S2 and Figs. S1 and S2.
1 To whom correspondence may be addressed: School of Medicine and
Dentistry, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZP,
United Kingdom. Tel.: 44-1224-438563; Fax: 44-1224-555173; E-mail:
c.harrington@abdn.ac.uk.
2 To whom correspondencemay be addressed: School of Medicine and Den-
tistry, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZP, United
Kingdom. Tel.: 44-1224-438550; Fax: 44-1224-555173; E-mail: cmw@
taurx.com.
3 The abbreviations used are: AD, Alzheimerdisease;DMMTC, dimethylmeth-
ylthioninium chloride; ER, endoplasmic reticulum; IPTG, isopropyl thio--
D-galactoside; LMT, leucomethylthioninium; LMTB, LMT-dihydrobromide;
LMTM, LMT-dihydromesylate; MT, methylthioninium; MTC, methyl-
thioninium chloride; MW, methylene white; PHF, paired helical filament;
SS, signal sequence; TAI, Tau aggregation inhibitor.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 290, NO. 17, pp. 10862–10875, April 24, 2015
Author’s Choice © 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
10862 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 17•APRIL 24, 2015
 at U
niversity of A
berdeen on M
ay 28, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
The primary motivation in developing the cell assays that we
report has been to aid the optimization of TAIs, as an interme-
diate between primary screening and testing in transgenic ani-
mal models, prior to clinical testing. Methylthioninium chlo-
ride (MTC; commonly known as “methylene blue”), the first
reported TAI, reverses the proteolytic stability of PHFs isolated
from AD brain tissues in vitro without disrupting normal Tau-
tubulin interactions (9). MTC is a stable heterocyclic ionic
molecule, which may exist in equilibrium, depending on envi-
ronmental conditions (e.g. pH, level of oxygenation, and the
presence of oxidizing or reducing agents), with its oxygen-sen-
sitive redox couple, leucomethylthionium (LMT; also known as
“methylene white” (MW)) (Fig. 1A). A phase 2 clinical trial in
mild/moderate AD identified a dose of 138 mg of MT/day,
administered as MTC, as the minimum effective dose on clini-
cal and imaging outcomes at 24 weeks (10). However, a dose of
228 mg of MT/day had either no efficacy or limited efficacy on
the same end points, due to limitations in the ability to absorb
the MT in its cationic form (11). This is because MTC behaves
effectively as a pro-drug that requires active reduction to the
uncharged LMT form in the gut to permit absorption by passive
diffusion and subsequent distribution to the brain (11). As a
result of dose-dependent limitations in this process, the 138mg
ofMT/day dose was simply the highest available dose, and test-
ing for efficacy and safety of higher doses of MT is not feasible
clinically using MTC (10).
In order to overcome this limitation, we report the synthesis
of novel chemical entities (which we denote LMTX) in which
the reduced LMT form can be provided directly as a stable
anhydrous crystalline salt suitable for pharmaceutical develop-
ment. We use the new cell assays to analyze different diprotic
salt forms of LMT and show that they retain TAI activity within
the physiological milieu of the cell. We use the assays to deter-
mine that the intracellular Ki for activity of MT at the Tau
aggregation site is 0.12 M. This value is close to the P50 value
for disaggregation of PHFs isolated from AD brain (0.16 M),
the minimum brain concentration (0.13 M) required to
reverse behavioral deficits and reduce Tau pathology in Tau
transgenic mice (12), and the estimated steady state trough
brain concentration of MT and its pharmacologically active
demethyl derivatives (0.18 M) at the minimum effective dose
found to be required for arresting the progression of AD (11).
EXPERIMENTAL PROCEDURES
Compounds—10-Acetyl-N,N,N,N-tetramethyl-10H-phe-
nothiazine-3,7-diamine was synthesized and used as the start-
ing material for the synthesis of N,N,N,N-tetramethyl-10H-
phenothiazine-3,7-diaminium dibromide (which we denote
leucomethylthioninium dihydrobromide for convenience;
LMTB) and N,N,N,N-tetramethyl-10H-phenothiazine-3,7-
diaminium bismethanesulfonate (which we denote leucometh-
ylthioninium dihydromesylate; LMTM). Detailed syntheses
can be found in the supplemental material. MTC was pur-
chased from Simpsons (Gwent, UK). 1,9-Dimethyl methyl-
thioninium chloride (listed as “1,9-dimethylmethylene blue”
and which we refer to as DMMTC) was purchased from Serva.
The structures of these compounds are shown in Fig. 1B.
Polymorphism Analysis of LMTM—A polymorphism analy-
sis was conducted by Solvias AG (Kaiseraugst, Switzerland) to
investigate the predisposition of LMTM to show polymor-
phismor hydrate formation. Two types of crystallization exper-
iment were conducted: suspension equilibrations, generally
considered the most reliable way to discover stable polymor-
phic forms, and cooling crystallizations, which increase the
probability of identifying kinetically preferred but thermody-
namicallymetastable polymorphic forms fromhighly saturated
solutions. Both FT-Raman spectroscopy and powder x-ray dif-
fraction were used to analyze samples (13).
PHFs and Tau Proteins—PHFs were purified from AD brain
as described previously (2). Fragmented PHFs, termed ABCsup
(14), were used for the primulin-binding P50 assay. Recombi-
nant Tau fragments dGA and dGAE, corresponding to amino
acids 297–390 and 297–391, respectively, of the largest human
Tau isoform in the central nervous system (15), were expressed
in bacteria. These proteins were purified from bacterial cell
lysates using P-11 phosphocellulose ion exchange chromatog-
raphy (16).
Primulin-binding Assay (P50)—The disruption of PHFs was
monitored by the effect of compounds on enhanced PHF-de-
pendent fluorescence measured using primulin binding to
PHFs. Samples were assayed in 96-well white plates (100-l
volumes) in the presence of primulin (1 M) and test com-
pounds at appropriate concentrations. The fluorescence was
measured in a Varian Carey Eclipse fluorescence spectrometer,
and the excitation spectrum was measured with the emission
wavelength at 480 nm. Peak fluorescence at an excitation wave-
length of 420 nm was measured from spectra after correction
for the signal measured in the absence of PHFs. The P50 was
calculated as the concentration of compound at which the fluo-
rescence is reduced to 50% of the value in the absence of
compound.
Tau-Tau Binding Assay (B50)—Compounds were tested for
inhibition of Tau-Tau binding using an ELISA-based assay (9).
The Tau fragment dGA, at 1M in 50mM carbonate buffer (pH
9.6), was adsorbed to the surface of 96-well poly(vinyl chloride)
plates. After blocking with 2% driedmilk powder in phosphate-
buffered saline (PBS), dGAE (0.15M in 25mMK-PIPES, 50mM
NaCl, 0.05%Tween 20, 1% fish skin gelatin, pH 6.8) was added
with test compounds. All incubations were at 37 °C for 60 min.
Bound antibody was detected as described previously (9). The
B50 value was calculated as the concentration of inhibitor at
which specific binding was reduced to 50% of the value in the
absence of inhibitor.
Inducible Tau(1–441) (hTau40) Vector—A cell line express-
ing full-length human Tau was constructed using the Lac-
Switch (Stratagene) system in which Tau is expressed under
control of the lac repressor protein. 3T6 cells (ECACC number
86120801 mouse Swiss albino embryo fibroblasts) were trans-
fected, by electroporation, with the p3SS plasmid, which
encodes the lac repressor protein, and colonies were selected
for hygromycin resistance (3T6H cells). ANotI cloning site was
introduced into hTau40 cDNA to allow cloning of Tau into the
pOPRSVICAT vector by PCR-basedmutagenesis using the fol-
lowing primers: forward primer, 5-gtcgactctagaggcggccgcatg-
gctgagccccggcaggag-3; reverse primer, 5–actcttaagggtcgcg-
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gccgctcacaacaaaccctgcttggccag-3. The insert was ligated into
the vector, and the correct orientation of the inserts was con-
firmed by restriction digest mapping.
The pOPRSVT40 plasmid was transfected by electropora-
tion into 3T6H cells, and clones were selected for resistance to
G418. The expression of full-length hTau40 was induced using
isopropyl -d-1-thiogalactopyranoside (IPTG).
Expression of hTau40 with SSTau Constructs—The expres-
sion system used for production of membrane-associated Tau
fragments is based on the observation that rabbit globinmRNA
A
D
C
B
i
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10
FIGURE1.Characterizationof compounds.A, redox conversionofMTC to leucomethylthioninium.B, structuresof compounds tested in assays:MTC,DMMTC,
LMTM, and LMTB.C, scheme for synthesis of LMTM fromMTC. i, N2H4H2O, Et3N, CH3CN,N2, 70 °C, 1 h; ii, Ac2O, N2, 95 °C, 2 h; iii,methanesulfonic acid, H2O, 78 °C,
2.5 h; iv, EtOH. Details are provided under “Experimental Procedures.”D, x-ray structures ofMTC (22) (i), MW (ii), and LMTM (iii). The nitrogen atoms at positions
3 and 7 are planar in the case of MTC or pyramidal in the case of MW (black arrows) and tetrahedral for LMTM (red arrows).
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is translated on membrane-bound ribosomes if the signal
sequence (SS) of rat albumin is inserted at the 5 end of the
cDNA (17). The vector described previously for expression of
globin was modified to incorporate fragments of Tau coding
sequence downstream of the signal sequence while at the same
time maintaining the globin 3-untranslated region.
Three vectors expressing truncated forms of Tau protein
(residues 296–390, 190–441, and 190–390) and referred to
as SSTau(296–390), SSTau(190–441), and SSTau(190–390),
respectively, were constructed. PCR-based mutagenesis on
pcKSSGG (17) was used to introduce an AgeI site at the
globin start codon to make pcKSSGGAgeI (forward primer,
5-gccttttcaccggtgcatctgtcca-3; reverse primer, 5-tggac-
agatgcaccggtgaaaaggc-3). For pcKSSTau(190–441), PCR-
based mutagenesis on hTau40 introduced an AgeI site at
nucleotide 1128 of hTau40 (forward primer, 5-tctggtgaa-
ccggtaaaatcagggg-3; reverse primer, 5-cccctgattttaccggttc-
accaga-3). The fragment was cut with EcoRI beyond the
Tau stop codon, blunt-ended, cut with AgeI, ligated into
pcKSSGGAgeI, cut with BamHI, blunt-ended, and then cut
with AgeI to make pcKSSTau(190–441). The ligation pro-
cess results in Lys-190 becoming the start of the Tau
sequence. For pcKSSTau(190–390), PCR-basedmutagenesis
on pcKSSTau(190–441) introduced a BamHI site and a stop
codon at nucleotide 1740 (which terminates the Tau
sequence at Ala-390) (forward primer, 5-cggggcgtatccgtac-
aagtcg-3; reverse primer, 5-cgacttgtacggatcctacgccccg-3).
The fragment was cut with AgeI and BamHI and ligated into
pcKSSGGAgeI at the same sites to make pcKSSTau(190–
390). For pcKSSTau(296–390), PCR-based mutagenesis on
pcKSSTau(190–390) introduced an AgeI site at nucleotide
1450 of pcKSSTau(190–390) (forward primer, 5-ggctcacc-
ggttaatatcaaac-3; reverse primer, 5-gtttgatattaaccggtga-
gcc-3). The fragment was cut with AgeI and BamHI and
ligated into pcKSSGGAgeI at the same sites to make
pcKSSTau(296–390). These constructs were created using the
expression vector pcDNA3.1, which carries the G418 resistance
marker. All were subcloned into the pcDNA3.1/Zeo vector (Invit-
rogen, Leek, Netherlands), which contains the Zeocin resistance
marker, for transfection into the inducible hTau40 cell line.
Expression of hTau40 with Constitutive Tau(295–391)—For
construction of the plasmid pZeo(295–391), designed to
express protein corresponding to a truncated fragment of Tau
(residues 295–391), EcoRI and BamHI cloning sites were intro-
duced by PCR amplification of hTau40 cDNA (forward primer,
5-cggaattccaccatggataatatcaaacacgtcccg-3; reverse primer,
5-cgcgggatcctcactccgccccgtggtctgtcttggc-3). The constructs
were subcloned into pcDNA3.1/Zeo() for transfection into
the hTau40 cell line.
Cell Culture—Cells were grown in Dulbecco’s modified
Eagle’s medium (with Glutamax I, pyruvate, 4.5 g/liter glucose;
Life Technologies), supplemented with 10% fetal calf serum
(Helena BioSciences), 50 units/ml penicillin, 50 g/ml strepto-
mycin, and further antibiotic as appropriate for the selection
and maintenance of the relevant plasmids. Hygromycin (200
g/ml) and G418 (500 g/ml) were included for both selection
andmaintenance of the hTau40 cell line, and 400 or 200 g/ml
Zeocin was used for selection or maintenance, respectively,
of SSTau(190–441), SSTau(190–390), SSTau(296–390), and
pZeo(295–391). Cells were grown at 37 °C, in a humidified
atmosphere containing 5% CO2.
Cell-based Tau Aggregation Assay (EC50)—The cell-based
Tau aggregation assays used the cell lines described above,
which express inducible full-length hTau40 in combination
with constitutive expression of one of the Tau fragments
selected from SSTau(190–441), SSTau(190–390), SSTau(296–
390), and Tau(295–391) (see Fig. 2). Expression of hTau40 was
induced by the addition of IPTG (10–50 M); in the case of cells
expressing theSSTau fragments, their expressionwas increasedby
the addition of sodiumbutyrate (5mM), a nonspecific enhancer of
protein expression (18, 19).
For testing of compounds, cells were incubated with com-
pounds in 24-well plates, and after 24 h, IPTG was added to
the medium. After overnight incubation, the medium was
removed, and cells were washed with PBS and then taken up
with Laemmli buffer. Samples were separated by SDS-PAGE,
transferred to PVDF membrane, and reacted with mAb 7/51
antibody (14, 20). Bound Tau antibody was detected using
enhanced chemiluminescence. Compounds were typically
tested at four concentrations, each in triplicate, with all samples
being separated on a single gel. To control for any variability in
expression of hTau40, we use the ratio of the intensities of the
truncated 12 kDa to full-length hTau40 protein bands. The val-
ues, normalized to those obtained for control samples in which
there had been no test item, were plotted against compound
concentration. The EC50 value was determined as the concen-
tration at which the ratio was 50% of the value obtained in the
absence of compound.
Tau Antibodies—The following Tau antibodies were used:
mAbs 7/51 (epitope inmicrotubule-binding repeat domain (14,
20)); 27/499 (N-terminal epitope in residues 14–26 (9)); 27/342
(epitope in residues 208–251 (9)); and T46 (C-terminal epitope
in residues 395–432; Invitrogen).
Cellular Toxicity—Toxicity was determined using the Cyto-
tox 96-well kit (Promega), according to the manufacturer’s
instructions. The LD50 was determined as the concentration in
the assay at which the absorbance at 490 nm was decreased by
50%.
FIGURE 2. Tau constructs used in cell models. Full-length Tau (hTau40;
amino acid residues 1–441)was used in an inducible vector systemdescribed
under “Experimental Procedures.” The hTau40 cell line was then transfected
with truncated Tau fragments that are expressed constitutively to generate
twodifferentmodels: eitherwithoneof a series of SSTau constructs of various
lengths or with truncated Tau(295–391) without the SS.
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Immunofluorescence—3T6 cells expressing Tau were grown
on glass coverslips for microscopy. Cells were fixed either in
0.3% glutaraldehyde containing 0.1% TritonX-100 or in para-
formaldehyde for 20 min followed by extraction with 0.2% Tri-
ton X-100. In some cases, cells were extracted with saponin
(0.5% in 80 mM K-PIPES, 1 mM MgCl2, 1 mM EGTA, 30% glyc-
erol, pH 6.8) for 2 min and then fixed in 0.3% glutaraldehyde in
the same buffer for 10 min. Saponin (0.5%) was included in
subsequent antibody incubations and washes. Saponin is a rel-
atively mild detergent that leaves internal membranes intact,
whereas Triton X-100 will expose the lumenal surface of
internal organelles. Cells were then labeled by incubation for
1 h at room temperature with mAb 7/51 (hybridoma superna-
tant fluid diluted 1:10 in PBS containing 0.05% Tween 20).
Antibody was detected using goat anti-mouse FITC conjugate.
The rat mAb YL1/2 was used for visualization of microtubules
(21). Cells were examined by fluorescence microscopy.
RESULTS
Synthesis andManufacture of LMTas Pure Stable Crystalline
Salts—We report the development of an industrially scalable
synthesis of LMT salts as novel chemical entities (LMTX)
using crude MTC as the starting material (organic purity less
than 97% and metal impurity in excess of 20 g/g). The syn-
thetic scheme for the dihydromesylate salt, as an example, is
shown in Fig. 1C, whereas details of the synthesis are provided
in the supplemental material.When scaled up, the final crystal-
line product was isolated in 84% yield on a 90-kg industrial
synthesis with a 99.7% organic purity and heavy metal content
within the permitted European Pharmacopoeia limits specified
for MTC (see supplemental Table S1).
The single crystal, x-ray structural determinations of MTC
(22); the oxygen-sensitive, uncharged LMT (MW) (stored
under argon); and the oxygen-stable, protonated LMTM are
compared in Fig. 1D. The core ring system ofMTC is planar, as
expected for a completely delocalized system; in contrast, MW
and LMTMhave non-planar central heterocyclic rings, consis-
tent with the reduced form. The x-ray crystallography for
LMTM confirmed that the nitrogen atoms at positions 3 and 7
had tetrahedral geometry and hence were protonated. Pro-
tonation of the nitrogen atoms contributes to both the
geometry of LMTM and its stability in an oxygen atmo-
sphere and differentiates it from MW, which has trigonal
pyramidal nitrogen geometries. These structures distinguish
the protonated LMTM fromMWand confirm that LMTM is
a distinct chemical entity.
Of the LMTX salt forms investigated (dihydrobromide and
dihydromesylate), LMTM exhibited optimal characteristics in
terms of crystal properties, purity (99.7%), stability to oxidation,
and process scalability. LMTM is substantially more water-sol-
uble thanMTC (1,700 and 18mg/ml, respectively) and exists as
a single polymorph (see Raman spectrum and x-ray diffraction
pattern of the LMTM polymorph in supplemental Figs. S1 and
S2). The LMTM polymorph does not change on storage at
30 °C and 65% humidity over 24 months (see supplemental
Table S2).
Dissolution of PHFs Isolated from AD Brain Tissues—A fluo-
rometric assay was developed to measure dissolution of PHFs
isolated fromADbrain tissue. The addition of PHFs to primulin
solution induces a PHF concentration-dependent increase in
fluorescence at an excitation wavelength of 420 nm, not seen in
the absence of PHFs (Fig. 3A), due to the binding of primulin to
PHFs (23). A compound based on the primulin scaffold had
been used previously to provide the first identification and
sequencing of the core Tau unit of the PHF (2), establishing
compounds of this type as PHF core ligands. The addition of
MTC, previously shown to reverse the proteolytic stability of
the PHF core (9), produced concentration-dependent disrup-
tion of fluorescence enhancement. Disruption of the primulin-
binding can be distinguished from competition at the ligand
binding site by its independence from primulin concentration
(Fig. 3B). This contrasts with competitive ligands, such as thia-
zine red, where competition can be overcome by increasing the
FIGURE 3. Disruption of PHFs by MT. A, PHF-dependent fluorescence excitation spectra (emission wavelength, 480 nm) measured with primulin and
increasing concentrations of PHFs (2, 5, and 10 l of PHFs, indicated by red, blue, and green profiles, respectively). The spectra shown have been corrected for
signal measured in the absence of PHFs. B, PHF-dependent fluorescence at increasing concentrations of MTC in the presence of primulin at 0.2–2 M, as
indicated, with 10 l of PHFs. The fluorescence signal measured at 420-nm excitation and 480-nm emission was corrected by subtraction of the signal
measured in the absence of PHFs andnormalized to the signalmeasured in the absence ofMTC. Therewas nodifference inMTC inhibition of fluorescence over
the range of primulin concentrations tested. C, thiazine red (TR) at 0.1Mbinds to PHFs as a ligand and inhibits fluorescence seenwith primulin at 0.2M (note
the expanded vertical scale for normalized fluorescence). This inhibition can be reduced by increasing the primulin concentration to 1 M, indicating that
inhibition of primulin binding is competitive. By contrast, the inhibition of fluorescence produced by 0.1 M MTC cannot be reduced by increasing the
concentration of primulin from 0.2 to 1.0 M, consistent with disaggregation of PHFs by MTC reported previously (10).
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concentration of primulin (Fig. 3C). Thiazine red is a ligand that
also binds PHFs in AD neurofibrillary tangles (24). Thus,
whereas the primulin-binding site remains intact after thiazine
red binding, MT destroys the PHF core structure, consistent
with previous electron microscopic evidence and reversal of
proteolytic stability (9).
We denote the value required for 50% disruption of PHF-
primulin binding as the P50 value (Table 1). The P50 values for
MTC, the 1,9-dimethyl-substituted MTC (DMMTC), LMTM,
and LMTBwere 0.16, 0.18, 0.16, and 0.16M, respectively. The
structures of these compounds are shown in Fig. 1B.
Inhibition of Tau-Tau Binding through the Repeat Domain in
Cell-free Assays—We have previously shown that diaminophe-
nothiazines selectively inhibit Tau-Tau aggregation in vitro (9).
The inhibitory activities (B50) of a range of diaminophenothia-
zines were compared using this assay (Table 1). DMMTC was
almost 50-fold more potent than MTC (p  0.0001). The dif-
ference between MTC and LMTM was not statistically signifi-
cant (p 0.29), but LMTB had lower potency than MTC (p
0.0001).
Membrane-targeted Cellular Model of Tau Aggregation—
Stable cellular expression of the Tau aggregation domain of the
PHF core in eukaryotic cells is difficult due to its inherent tox-
icity using a number of different vectors and cell lines (25–27)
and is insufficient alone to induce aggregation (28). We were
able to solve this problem initially by targeting the localization
of the truncated Tau fragment to the membrane of the endo-
plasmic reticulum (ER), using a fusion protein comprising an
18-amino acid signal sequence (SS) (17) at theN terminus of the
Tau fragment. 3T6 cells, expressing inducible full-length
hTau40, under the control of the lac repressor, were co-trans-
fectedwith vectors containing SS constructs encoding Tau spe-
cies truncated to variable extents at the N and/or C terminus
(SSTau(190–441), SSTau(190–390), and SSTau(296–390); see
Fig. 2).
Large aggregates, some filamentous in appearance, were
observed clustered in the perinuclear area in cells transfected
with membrane-targeted constructs. Perinuclear accumula-
tions of Tau immunoreactivity were observed in cells with
either SSTau(190–390) (Fig. 4, A and B) or SSTau(190–441)
(Fig. 4, C and D). Furthermore, the appearance of the Tau was
similar for cells expressing SSTau(190–441) in which co-ex-
pression of hTau40 had been induced (Fig. 4, E and F). In con-
trast, stable transfectants for the membrane-targeted mini-
mum aggregation domain (SSTau(296–390)) expressed lower
levels of protein as detected using mAb 7/51. Tau immunore-
activity was observed in a reticular pattern consistent with its
association with the ER membrane (Fig. 4G), but dense aggre-
gates of Tau were not observed in cells with SSTau(296–390).
Tau antibody labeling of the SSTau(296–390)-transfected cells
was still observed when cells had been permeabilized with
saponin prior to fixation (Fig. 4H), indicating that the pro-
teins were oriented on the cytoplasmic surface of membrane
organelles. There was no microtubule labeling observed with
SSTau(296–390) expression following saponin extraction and
using glutaraldehyde as a fixative to preserve microtubules. In
contrast, with the SSTau(190–441), microtubules were labeled
in the same conditions using mAb 7/51 (Fig. 4J). Either the
SSTau(190–441) protein is sufficiently long to bind to micro-
tubules while still being attached to the ER in a cytoplasmically
oriented direction or the Tau is released into the cytoplasm,
where it binds to microtubules. Either way, this contrasts with
the behavior of the SSTau(296–390) species.
Paraformaldehyde was found to be a better fixation method
for visualization of SSTau aggregates, although this method
does not give good fixation of microtubules (29). The perinu-
clear aggregates seen with SSTau(190–390) (Fig. 4K) were dis-
persed after treatment of cells with nocodazole (Fig. 4L). This is
again consistent with an association of the Tau with intracellu-
lar organelles; nocodazole causes fragmentation and dispersion
of the perinuclear Golgi apparatus throughout the cytoplasm
(30).
Cell lysates were analyzed by immunoblotting to character-
ize the Tau products in these stable transfected cell lines (Fig.
5). When SSTau(190–441) (apparent molecular mass 40
kDa) was co-expressed in fibroblasts with the inducible hTau40
plasmid, 25-kDa/30-kDa neofragments recognized by mAb
7/51 were generated after induction with butyrate, IPTG, or
IPTGplus butyrate. IPTGwithout butyrate was able to increase
the level of the 25-kDa truncation product compared with
uninduced cells (Fig. 5A, left). Increased production of these
fragmentswas not seenwhen cells expressing SSTau(190–441)
alone were induced with butyrate, IPTG, or both (Fig. 5A,mid-
dle). The 25- and 30-kDa neofragments were not seen at all in
cells expressing full-lengthTau alone (Fig. 5A, right-hand lane).
This indicates that the SSTau(190–441), unlike full-length
Tau, can be processed to produce the 25-kDa fragment without
induction. Enhanced production of the 25-kDa neofragment
following induction with IPTG suggests that there is capture of
hTau40 by the SSTau(190–441), which leads to enhanced gen-
eration of characteristic truncation products.
The N- and C-terminal extent of these truncation products
was partially characterized by analyzing cell lysates with a panel
of Tau antibodies recognizing regions of Tau outside the repeat
TABLE 1
Inhibition of PHF dissolution, Tau-Tau binding, and Tau aggregation in cells by MTC, DMMTC, LMTM, and LMTB
P50, concentration at which there is 50% decrease of PHF-dependent primulin binding; B50, concentration at which Tau-Tau binding in a cell-free assay is inhibited by 50%;
EC50, effective concentration at which aggregation-dependent production of truncated Tau is inhibited by 50% in cells; LD50, dose at which 50% of 3T6mouse cells are killed
(as measured by LDH release assay). RxI (therapeutic index) LD50/EC50. Data are expressed as the mean (M) S.E. with the number of replicate experiments indicated
in parentheses.
Compound P50 B50 EC50 LD50 RxI
M M M M
MTC 0.159 0.013 (4) 195.6 16.1 (10) 0.59 0.04 (73) 65 5 (38) 110
DMMTC 0.180 0.011 (3) 4.3 0.5 (19) 0.041 0.004 (22) 3.5 0.97 (6) 85
LMTM 0.159 0.007 (3) 238.2 74.2 (3) 0.19 0.04 (9) 34 4 (8) 179
LMTB 0.156 0.005 (3) 472.4 22.6 (4) 0.66 0.15 (8) 61 4 (20) 92
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domain. The 18-, 25- and 30-kDa fragments all contain the core
aggregation domain ofTau that is recognized bymAb7/51. The
fragments produced from SSTau(190–441) have lost either the
N-terminal (25 kDa) or C-terminal domain (30 kDa) (Fig. 5B),
whereas the 18-kDa fragment produced from SSTau(190–390)
lacks both the N- and C-terminal domains (Fig. 5C).
Both of the SSTau proteins and the novel truncation prod-
ucts were readily sedimented from cell extracts in the presence
of Triton X-100, indicating the formation of detergent-resis-
tant aggregates. A fraction of the protein sedimented as parti-
cles with an apparent S value of at least50 S, consistent with
aggregation to a complex of 1–2  106 Da consisting of
100-mers of truncated Tau neofragments.
DMMTC, the most potentMT-related TAI noted above in
Table 1, was tested in cells with constitutive expression of
SSTau(190–441) and inducible hTau40. In the presence of
DMMTC at concentrations of 0.2 and 0.5 M, the capture
of full-length Tau to form the 25-kDa neofragment was
inhibited (Fig. 6).
Non-membrane-targeted Cellular Model of Tau Aggrega-
tion—The use of membrane targeting produced template-di-
rected, proteolytic neofragments that did not correspond
A B C D 
E G 
I J K L 
F H 
SStau190-390 SStau190-441
SStau190-441  +  htau40 SStau296-390
formaldehyde/Triton X-100            saponin/glutaraldehyde
SStau190-441
formaldehyde/Triton X-100            saponin/glutaraldehyde
SStau190-390
              butyrate                             butyrate + nocodazole
FIGURE 4. Immunofluorescence labeling of fibroblasts transfected with ER membrane-targeted constructs. A–H, perinuclear, Tau-immunoreactive
deposits were observed in cells transfectedwith truncated Tau constructs SSTau(190–390) (A and B), SSTau(190–441) (C andD), or SSTau(296–390) (G andH).
The deposits were also observed in cells following induction of co-expressed hTau40 (E and F). Aggregates of SSTau(296–390) were more dispersed into the
cytoplasm than the longer construct and remained granular in appearance following saponin treatment (H). The Tau from the longer construct, SSTau(190–
441), was competent in associating with microtubules (J). Perinuclear aggregates formed with SSTau(190–390) (K) are distributed throughout the cytoplasm
following treatment of nocodazole (L), a treatment that both depolymerizes microtubules and disperses the perinuclear stacks of Golgi and ER elements
throughout the cell. Cells were treatedwith butyrate (A–D andG–K), with butyrate and IPTG (E and F), or with butyrate plus nocodazole (10M for 1 h) (L). Cells
were fixed with paraformaldehyde followed by extraction with Triton X-100 with the exception of cells that were extracted with saponin and then fixed in
glutaraldehyde (H and J). All cells were labeled using mAb 7/51. Scale bars, 10 m.
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exactly to the PHF coreTauunit. An alternative cellular assay of
Tau aggregation, therefore, was developed in which cells
expressing inducible full-length hTau40were stably transfected
with pZeo-Tau(295–391), corresponding to the PHF core Tau
fragment (Tau(295–391)). The doubly transfected cell line
demonstrates the formation of aggregates of Tau that were
visualized using the fluorescent PHF ligand primulin only after
induction with IPTG (Fig. 7A). In these cells, low levels of con-
stitutive, 12-kDa truncatedTau, corresponding to the PHF core
Tau unit (Fig. 7B, arrow) and a low level of full-length Tau (Fig.
7B, arrowhead), were expressed in the uninduced condition.
IPTG-induced expression of full-length Tau led to its conver-
sion to the 12-kDa truncated species (Fig. 7B). This did not
occur in cell lines in which full-length Tau had been induced in
the absence of the co-expressed core Tau fragment (Fig. 5A,
third panel).
In this cell model, the normal microtubule network was
unaffected by the Tau induction process or by constitutive
expression of Tau(295–390) (Fig. 8). The tubulin-staining
pattern was similar, whether or not cells had been induced
with IPTG. By contrast, the Tau labeling with mAb 7/51 was
distinct from that observed in cells lacking the truncated
Tau species. Expression of induced full-length Tau on its
own showed a typical microtubular pattern of staining with
mAbs 27/499 and 7/51 (Fig. 8, E and F). This was not seen for
cells co-expressing both full-length and truncated Tau pro-
teins (Fig. 8D). The latter showed only a granular staining
pattern that is more clearly seen in a cell at greater magnifi-
cation (Fig. 8H). Therefore, full-length Tau induced in the
presence of the PHF core unit is processed through an aggre-
gation/proteolysis pathway that prevents association with
microtubules.
A
B 
C
SS 
27/499 27/342 7/51 T46 
190 390 
266 
441 
htau40 
SStau190-441 
(40 kDa) 
30 kDa 
25 kDa 
27/499 27/342 7/51 T46 
SS 
390 
266 390 
htau40 
SStau190-390
(32 kDa) 
18 kDa 
SStau190-441 
(40 kDa) 
htau40 
30 kDa 
25 kDa 
kDa 
80
50
34
29
21
  7
U      B     I      BI       U     B      I      BI        I
SStau190-441
+htau40 SStau190-441 htau40
SStau190-441 + htau40
B     I          B      I          B      I          B      I
7/51            T46            499             342
7/51            T46             499              342
SStau190-390 + htau40
B      I         B      I          B      I          B      I
FIGURE 5. Aggregation and proteolytic processing of Tau in cells containing SSTau constructs. A, 3T6 cells constitutive for SSTau(190–441) combined
with inducible hTau40 (left), constitutive for SSTau(190–441) alone (middle), orwith inducible hTau40 alone (right) were analyzed. Cellswere treatedwith 5mM
butyrate, 50M IPTG, or both, as indicated, for 24 h before separating by 15% SDS-PAGE and analyzing immunoblots usingmAb 7/51 (recognizing an epitope
within themicrotubule-binding repeatdomain).BandC, epitopeanalysis of Tau truncationproducts. Cellswith constitutiveSSTau(190–441) (B) or SSTau(190–
390) (C) combined with inducible hTau40 were treated with either butyrate or IPTG and analyzed by SDS-PAGE. The identity of the reactive Tau fragments is
depicted schematically on the right, based upon the apparentmobility and immunoprofile, although the numbers for the N and C termini are approximations.
U, uninduced; B, butyrate-induced; I, IPTG-induced.
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We have found this model to be reliable and reproducible as
a systematic secondary screen for intracellular TAI activity.
Results are expressed in terms of reduction in the ratio of the
truncated 12-kDa species to induced full-length hTau40, per-
mitting control for different background expression levels.
Normalized inhibition is expressed relative to the induced con-
dition in the absence of inhibitor. DMMTC, MTC, LMTB, and
LMTM all inhibited conversion of full-length Tau to the
12-kDa species following IPTG induction of full-length Tau
(Fig. 7,C–F, and Table 1). The EC50 values forMTC and LMTB
were comparable and not statistically different (p  0.67). By
contrast, LMTM was 3-fold more potent than MTC in the cell
assay (p  0.0001). The Spearman correlation for EC50 versus
B50 values was 0.80, indicating a surprisingly similar ranking of
potencies in the cell-free and intracellular assays for TAI activ-
ity, despite the considerable differences in absolute values.
Using the Kd value (21.1  2.9 nM) determined in vitro for
binding of full-length Tau in the aqueous phase to the PHF core
fragment in the solid phase (31), and assuming the intracellular
concentration of Tau to be 500 nM, Ki values were calculated
using the following equation.
Activity 	Tau
/	Tau
 KD1 	inhibitor
/Ki (Eq. 1)
The Ki values estimated for MTC and DMMTC were 123 nM
and 4.4 nM, respectively.
The cellular toxicities (LD50 values) for the diaminophe-
nothiazines tested in the cells (Table 1) were used to estimate
their therapeutic indices (i.e. LD50/EC50). These indicate that
LMTM had the best profile in this series, and DMMTC the
poorest profile notwithstanding its higher potency as a TAI in
cell-free and cellular assays.
DISCUSSION
The body of work reported here aims to resolve several fun-
damental and interrelated problems encountered in the devel-
opment of the first treatment aiming to block the pathological
aggregation of Tau protein as a treatment for AD. We recently
reported that the treatment effects of MTC tested in a phase 2
clinical trial ofmild ormoderate ADwere highly determined by
a combination of redox processing in the gut and the ability
to absorb MT in the presence of food (11). Although MTC
dosed at a level of 138 mgMT/day was found to arrest progres-
sion of AD on a range of clinical and imaging outcomes, a dose
of 228 mg MT/day had lower than expected efficacy on the
same outcomes. This was due to dose-dependent limitations in
the ability to absorb MT when dosed in the oxidized cationic
form asMTC. Pharmacokinetic studies in transgenic Taumice
and humans have shown that dosing of MT in the stable
reduced form solves the absorption problem (11). One impor-
tant question, therefore, is to determinewhether reduced forms
of MT retain TAI activity in a range of assay systems.
A further closely related issue is to determine whether the
clinical benefit seen with MT at 138 mg/day is plausibly due to
TAI activity orwhether it is due to other potential activities that
have been proposed (reviewed in Ref. 32). This in turn depends
on defining the MT concentration required for dissolution of
native PHFs and the Ki for intracellular TAI activity. These
values can then be compared with estimates of the minimum
brain concentration of MT required for clinical efficacy in
humans (0.18 M) (11) and the minimum brain concentration
required for reversal of behavioral deficits and reduction of Tau
aggregation pathology in transgenic mouse models (0.13 M)
(12).
We first report the synthesis and physico-chemical charac-
terization of stabilized diprotic acid salts of LMT that we have
used in pharmacokinetic (11) and transgenic animal studies
(12). We refer to them as the novel chemical entity class,
LMTX. X-ray crystal structure determinations of LMTM
demonstrate that the nitrogen atoms at positions 3 and 7 have
tetrahedral geometry. The protonation of these atoms accounts
for both the geometry and the stability of LMTM and distin-
guishes the latter fromMW, in which the corresponding nitro-
gen atoms are in a trigonal pyramidal geometry and not proton-
ated. Synthesis of MW has to be performed under an inert
atmosphere because it rapidly oxidizes on exposure to air. This
property underlies the use of MW as an oxygen sensor to mon-
itor the security of sealed components, where it is converted to
the blueMT cation once such seals are broken (33). In contrast,
LMTMcan bemanufactured in bulkwithout the need for deox-
ygenation and remains stable for at least 2 years when open to
an air atmosphere. Thus, LMTM represents a new chemical
entity that is distinct from both MTC and MW. LMTM is
highly soluble and exists as a single polymorph, in contrast to
MTC,which is far less soluble anddemonstrates heterogeneous
polymorphism (13).
We have reported previously, on the basis of electronmicro-
scopic and biochemical evidence, that MTC is able to dissolve
proteolytically stable PHFs and convert the constituent Tau
protein into a form that is readily susceptible to proteases (9).
We now report a fluorescence assay in which it is possible to
quantify this activity and to distinguish PHF disruption from
competitive ligand-binding activity. The P50 values for this
activity for the range of MT derivatives we have studied are
0.16 M. The use of primulin as a sensor to report the aggre-
gated state of the core PHF is based on our previous evidence
DMMTC (µM)
0               0.2             0.5
U     I    I/B   U     I     I/B    U    I     I/B
htau40
SStau190-441
  (40 kDa)
25 kDa
FIGURE 6. Effect of DMMTC on Tau aggregation in cells co-expressing
constitutive SSTau(190–441) and inducible, full-length hTau40. Prior to
induction with IPTG, and in the absence of DMMTC, there are baseline levels
of hTau40 expressed in cells as well as low levels of SSTau(190–441) and its
25-kDa truncation product. When induced with IPTG alone, hTau40 expres-
sion was increased together with the amount of the 40- and 25-kDa Tau
truncation products. Butyrate induction alone (not shown) or induction
with both IPTG and butyrate increased the level of the 25-kDa truncation
product. In the presence of DMMTC, the capture of full-length Tau and its
conversion to the 25-kDa species was inhibited following either IPTG
induction or induction with both IPTG and butyrate. U, uninduced; I, IPTG-
induced; B, butyrate-induced.
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that primulin is the principle tangle-binding constituent of
crude commercial thioflavin-S preparations (23) and the use of
a compound based on the primulin scaffold to provide the first
identification and sequencing of the core Tau unit of the PHF
(2). The enhanced fluorescence is concentration-dependent
with respect to PHFs and is not seen in the absence of PHFs.We
U    B     I   I/B   m   U     B    I    I/B   U    B     I    I/B
DMMTC (µM)
0                0.05           0.2
0    5   10  20  50   0    5  10   20  50     0   5   10  20  50   0    5   10  20  50 [IPTG]  
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0               0.5               1.0              2.0 
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0              0.1             0.5              2.0 
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FIGURE 7.Cellularmodel of Tau aggregation and its inhibition byMT. A, fibroblasts, stably transfectedwith both constitutive truncated Tau(295–391) and
uninduced full-length Tau, express both proteins at low levels. Following induction with IPTG, cells showed labeling with primulin, a fluorescent PHF ligand.
This was absent for uninduced cells in the panel below ( IPTG). B, SDS-PAGE and immunoblotting of these cells shows that induction of full-length Tau at
increasing concentrations of IPTG (arrowhead) is associated with increased accumulation of the 12-kDa truncated Tau neofragment (arrow). C, a dose-depen-
dent inhibition of the generation of the 12-kDa protein from full-length Tau is shown for DMMTC at 0.05 and 0.2 M, following induction with IPTG, butyrate,
or both when compared with uninduced cells. D, MTC, tested using a range of IPTG concentrations, also inhibited generation of 12-kDa Tau. E, LMTM, tested
in triplicate at the same concentrations, but using 10M IPTG,was likewise inhibitory over the concentration range 0.1–2.0M. The positions of full-length and
truncated 12-kDa Tau are indicated by an arrowhead and arrow, respectively. F, inhibition curves are shown for LMTM, MTC, and DMMTC following induction
with 10 M IPTG (mean S.E. (error bars)). U, Uninduced; I, IPTG-induced; B, butyrate-induced.
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further distinguish reduction of primulin binding to PHFs that
is due to competing ligand activity from disruption of PHF
integrity by TAIs. The P50 values reported here therefore define
the concentration of TAI required for dissolution of native
PHFs isolated from AD brain.
In the in vitro Tau-Tau binding assay, in which truncated
Tau is in a partially aggregated state, the B50 values for MTC
and LMTM did not differ significantly; LMTB had a 2.4-fold
lower potency. DMMTC was found to have a 55-fold higher
potency thanMTC in the in vitroTau-Tau binding assay. It did
not, however, differ in potency in terms of PHF disruption.
Furthermore, the B50 values ranged between 24- and 3,000-fold
higher than the corresponding P50 values. These discrepancies
illustrate the importance of defining an assay for TAI activity
that has disease relevance. Differences in TAI activity between
PHFs and the in vitro assay are most likely due to differences in
the state of aggregation of the core Tau domain in vitro com-
pared with native PHFs formed within the brain and to difficul-
ties in controlling its autoaggregation in vitro. An important
corollary is that it is not possible to define the concentrations
required for TAI activity in vivo based solely on Tau aggrega-
tion or polymerization assays in vitro (34–38).
The difficulties encountered in controlling Tau aggregation
in vitro and the discrepancies with respect to actual PHFs from
AD brain suggest the need to model the process in a more
physiological setting within a living cell. This has proved diffi-
cult to achieve directly by simple overexpression, even when
using inducible expression vectors, due to the inherent cytotox-
icity of the core PHF Tau fragment. Although the exact form of
Tau that is toxic in AD and the cellular location of such toxicity
remain uncertain (25), we have observed toxicity of both trun-
cated Tau and PHF-Tau in Lipofectin transfectionmodels (39).
We now report the development of two novel cell models in
which it has been possible to induce Tau aggregation through
the repeat domain and to generate aggregation-dependent
truncation products within the physiological milieu of the cell.
We have used fibroblast cell lines that lack endogenous Tau
protein (40). In the first model, we have targeted the expression
of truncated Tau to the ERmembrane, where, at low levels, it is
capable of initiating the capture and aggregation of full-length
human Tau. Using truncated Tau proteins that incorporate the
repeat domain as initiators, we have demonstrated that cells are
able to generate two families of neofragments restricted to
either three or four repeats. The oligomers that are formed are
the equivalent of 100-mers of truncatedTauneofragments. The
combined expression of the truncated initiator species and full-
lengthTauprotein therefore leads to the processing of the latter
to form increased levels of characteristic truncated neofrag-
ments of Tau.
The generation of neofragments by directing truncated Tau
expression to the ER membrane is interesting in the light of
evidence that early amorphous aggregates of Tau in AD are
associated with mitochondria and ER membranes (41). Fur-
thermore, there is increased contact between mitochondria
and rough ER membranes in JNLP3 mice that express P301L
mutant Tau, and accumulation of Tau was identified in ER
membrane-enriched fractions from both these transgenic mice
and AD brains (42).
Whereas the SS-models demonstrate the principle of prion-
like processing of Tau protein, the neofragments generated are
larger than the PHF core domain that they all contain. We
found that, provided constitutive expression of the PHF core
fragment ismaintained at very low levels, long termcell viability
is possible. These low levels do not, however, permit aggrega-
tion to be studied. When such cells were co-transfected with
inducible, full-length four-repeat Tau, it was possible to induce
Tau aggregation and template-directed truncation of full-
length Tau in a controlledmanner. The neofragment generated
in a concentration-dependent manner with respect to induced
full-length Tau is simply the core Tau unit itself. This now
confirmswithin the physiologicalmilieu of the cell themodel of
propagation ofTau aggregation through the repeat domain that
we first reported on the basis of data in a cell-free system (9).
The repeat domain has the ability to define a template-directed
A B C D
FE G H
FIGURE 8. Immunocytochemical characterization of fibroblasts expressing both Tau(295–391) and inducible full-length Tau. The cells possessed
normal cytoskeletal morphology both before (A) and after IPTG induction (B), as indicated by the microtubular network labeled for tubulin with mAb YL1/2.
Labeling of Tau with mAb 7/51 showed that Tau was only detected after induction (C, without IPTG; D, with IPTG), and the pattern of staining observed was
associated with granular structures. By contrast, cells transfected with inducible full-length Tau, in the absence of truncated Tau(295–391), showed normal
microtubular networks after induction, whether labeled with mAbs 27/499 (E), 7/51 (F), or YL1/2 (tubulin; G). A higher magnification of a cell in (D) shows the
granular staining with mAb 7/51 in the doubly transfected cells following induction of full-length Tau in the absence of microtubule labeling (H). Cells were
fixed with 0.3% glutaraldehyde with 0.1% Triton X-100. Scale bars, 20 m.
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truncation of full-length Tau to reproduce and amplify the pro-
teolytically stable species characteristic of the PHF core in AD
(2, 9).
In this model, Tau aggregation can be demonstrated only
after induction of full-length Tau. Furthermore, whereas
induction of full-length Tau in the absence of the PHF core
fragment permits binding to microtubules, this does not occur
in cells co-expressing the PHF core fragment. Instead, newly
expressed full-lengthTau is preferentially directed to the aggre-
gation/truncation pathway. This is consistent with in vitro data
that we have reported previously showing that the binding
affinity for Tau-Tau binding is substantially higher than for
Tau-tubulin binding, although both occur through the repeat
domain (31). This may help explain the almost complete redis-
tribution of the Tau protein pool from microtubule-bound to
aggregated forms that is characteristic of AD (14) and indicates
that phosphorylation is not required to account for loss of
microtubule binding in AD (43, 44).
We have further demonstrated that template-directed trun-
cation can be inhibited in both cellular models by substances
shown to be TAIs in vitro. Indeed, the Spearman correlation for
EC50 versus B50 values was 0.80, indicating an approximately
similar ranking of potencies in the cell-free and intracellular
assays for TAI activity. This is despite the fact that the cell assay
requires an additional cell entry step. These data support the
aggregation dependence of template-directed truncation. It is
again important to note that the only exogenous manipulation
required to induce aggregation and prion-like processing is to
turn on the expression of full-length Tau in the presence of
a truncated Tau binding partner. The aggregation of Tau
through the repeat domain does not require phosphorylation
(45) or the formation of covalent bonds, as has been proposed
(46). The fact that Ki values can be calculated using a standard
kinetic model implies that Tau-Tau binding and its inhibition
are concentration-dependent, competitive, saturable, and re-
versible within the cell milieu, inconsistent with the formation
of covalent bonds (46).
Our findings with the two cell models are consistent with a
pathway of events summarized schematically in Fig. 9. (i)
Aggregation of Tau is seeded initially either by the membrane-
localized truncated Tau or by truncated Tau itself interacting
with full-length Tau. (ii) Cleavage of the N-terminal signal pep-
tide and/or the N and C termini of full-length Tau (iii) leaves
Tau oligomers in the cytoplasm. (iv) These oligomers allow
further capture of full-length Tau that enters the proteolytic
processing pathway. (v) Oligomers are susceptible to disaggre-
gation by TAIs, allowing for their subsequent clearance from
the cell.
The cellular evidence for Tau aggregation being seeded by
truncated Tau (47, 48) has been confirmed independently in
transgenic rat studies (49, 50). In the latter studies, insoluble
Tau aggregates formed in the brain consist of both transgenic
human truncated Tau and endogenous rat Tau in a 1:1 ratio.
This confirms, as predicted by the earlier in vitro data (9) and
the cell-based data described here, that truncated Tau coopts
normal Tau into a pathological aggregation pathway leading
ultimately to aggregates typically formedwithin neurons inAD.
This suggests that truncated Tau oligomers are sufficient to
drive neurofibrillary degeneration in the presence of full-length
Tau. Truncated Tau oligomers are also important for the trans-
mission of Tau pathology between neurons that has been estab-
lished in recent years (47, 48, 51).
Based upon the cell models described here, we have gone on
to create transgenic mice to demonstrate that truncated Tau
targeted to the ER membrane also leads to Tau aggregation in
vivo (52). The mice show evidence of neuroanatomical spread
of Tau aggregation pathology and amplification with age that
resembles the Braak staging of AD. Furthermore, MTC and
LMTX, which we have shown to be active inhibitors of Tau
aggregation, reduce Tau pathology and reverse the cognitive
behavioral deficits observed in thesemice (12). Treatment with
these compounds also reduced Tau pathology and reversed
behavioral deficits in a further transgenic Tau model for the
frontotemporal lobar degeneration spectrum based on full-
length mutant Tau (12).
Since we described the selective inhibition of Tau-Tau bind-
ing by MTC (9), several other Tau polymerization inhibitors
have been reported. These include bis-thiacarbocyanine (36,
53), Congo red derivatives and anthoquinones (37), 2,3-di-
(furan-2-yl)-quinoxalines (35), phenylthiazolyl-hydrazide (54),
polyphenols and porphyrins (38), oleocanthal (55), rhodanines
(56), and cyanin dyes (34). Some of these are toxic, and their
potency either as disruptors of PHFs in vitroor their activities in
more physiological intracellular conditions remains largely
PHF-core oligomers
SS
SS
+
+
TAIs Clearance
Tau
FIGURE 9. Schematic representation of Tau aggregation in cell models. Tau aggregation requires the presence of both a truncated Tau fragment (either
with or without the SS) and a full-length molecule of Tau protein. The combination of these, followed by proteolysis of larger Tau, restricted to the N and C
termini, leads to the accumulation of truncated PHF core Tau oligomers. Formation of the oligomers needed for template-directed truncation can be blocked
and their clearance can be enhanced by diaminophenothiazine TAIs.
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uncharacterized. The activity of some of these compounds has
been tested in neuroblastoma (57) or Caenorhabditis elegans
(58) models in which mutant Tau proteins have been used.
Because these mutations do not occur in AD, the relevance of
such models to the aggregation found in AD is unknown. Test-
ing such compounds in transgenic animal models is labor- and
time-intensive,making the cellmodelswe have described a use-
ful intermediate platform for lead selection and for optimiza-
tion for TAI activity. We illustrate this utility with DMMTC.
Although DMMTC is a highly potent TAI in both cell-free and
cellular assays for Tau aggregation, it is also a substantially
more toxic compound than MTC. LMTM, although having
lower potency thanMTC in cell-free and cell-based assays, nev-
ertheless has a better therapeutic index and has better bioavail-
ability in vivo (11).
Finally, the cell-based models permitting TAI activity to be
measured in a physiological milieu provide a means of estimat-
ing the intracellular Ki and linking this to the concentration
required for TAI activity in the human brain in AD. Thus, the
intracellular Ki for activity of MT at the Tau aggregation site is
0.12M.This value is close to the P50 value for disaggregation of
PHFs isolated from AD brain (0.16 M). These concentrations
are both close to the estimated steady state trough brain con-
centration of MT and its pharmacologically active metabolites
(0.18 M) at the minimum effective dose for treatment of AD
and the minimum brain concentration (0.13 M) required for
beneficial effects on behavior and pathology in Tau transgenic
mice. The cell models described here therefore offer potential
to investigate the process of aggregation in a living system, the
mechanism of action of TAIs, and to optimize themwith a view
to further clinical development. Because the P50 and Ki values
are both close to the brain concentration required for therapeu-
tic efficacy, the data do not as yet enable us to distinguish
whether it is the ability ofMTcompounds to disaggregate PHFs
and related oligomers, their ability to prevent their aggregation,
or a combination of these that is critical for clinical efficacy of
TAI therapy in AD and related disorders.
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